Abstract | PURPOSE: EXPERIMENTAL DESIGN:
CL-387,785 sensitivity and signal transduction in H1975 cells were examined in the presence or absence of HGF or HGF-producing fibroblasts with or without HGF-MET inhibitors. RESULTS: HGF reduced susceptibility to CL-387,785 in H1975 cells. Western blotting and small interfering RNA analyses indicated that HGF-induced hyposensitivity was mediated by the MET/ phosphoinositide 3-kinase/Akt signaling pathway independent of EGFR, ErbB2, ErbB3, and ErbB4. Hyposensitivity of H1975 cells to CL-387,785 was also induced by coculture with high-level HGF-producing lung fibroblasts. The hyposensitivity was abrogated by treatment with anti-HGF neutralizing antibody, HGF antagonist NK4, or MET-TKI. CONCLUSIONS: We showed HGF-mediated hyposensitivity as a novel mechanism of resistance to irreversible EGFR-TKIs. It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de novo and acquired resistance to irreversible EGFR-TKIs in lung cancer harboring T790M mutation in EGFR.
|
Authors | Tadaaki Yamada, Kunio Matsumoto, Wei Wang, Qi Li, Yasuhiko Nishioka, Yoshitaka Sekido, Saburo Sone, Seiji Yano |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 16
Issue 1
Pg. 174-83
(Jan 01 2010)
ISSN: 1557-3265 [Electronic] United States |
PMID | 20008840
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Protein Kinase Inhibitors
- Receptors, Growth Factor
- Hepatocyte Growth Factor
- ErbB Receptors
- MET protein, human
- Protein-Tyrosine Kinases
- Proto-Oncogene Proteins c-met
- Proto-Oncogene Proteins c-akt
- Mitogen-Activated Protein Kinase 3
|
Topics |
- Adenocarcinoma
(drug therapy, genetics)
- Drug Resistance, Neoplasm
- ErbB Receptors
(antagonists & inhibitors, genetics)
- Fibroblasts
(metabolism)
- Hepatocyte Growth Factor
(pharmacology)
- Humans
- Lung Neoplasms
(drug therapy, genetics)
- Mitogen-Activated Protein Kinase 3
(metabolism)
- Mutation
- Protein Kinase Inhibitors
(therapeutic use)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Proto-Oncogene Proteins c-akt
(metabolism)
- Proto-Oncogene Proteins c-met
(metabolism)
- Receptors, Growth Factor
(metabolism)
- Signal Transduction
|